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Background: Bacillus Calmette-Guérin (BCG) is considered the most effective treatment to reduce recurrence and
progression of non-muscle invasive bladder cancer (NMIBC) but can induce local side effects leading to treatment
discontinuation or interruption. Aim of this exploratory study is to investigate if the sequential administration of
Hyaluronic acid (HA) may reduce local side effects of BCG.
Methods: 30 consecutive subjects undergoing BCG intravesical administration for high risk NMIBC were
randomized to receive BCG only (Group A) or BCG and HA (Group B). A 1 to 10 Visual Analog Scale (VAS) for
bladder pain, International Prostate Symptom Score (IPSS) and number of micturitions per day were evaluated in
the two groups before and after six weekly BCG instillations. Patients were also evaluated at 3 and 6 months by
means of cystostopy and urine cytology.
Results: One out of 30 (3,3%) patients in group A dropped out from the protocol, for local side effects. Mean VAS
for pain was significantly lower in group B after BCG treatment (4.2 vs. 5.8, p = 0.04). Post vs. pre treatment
differences in VAS for pain, IPSS and number of daily micturitions were all significantly lower in group B. Three
patients in group A and 4 in group B presented with recurrent pathology at 6 month follow up.
Conclusions: These preliminary data suggest a possible role of HA in reducing BCG local side effects and could be
used to design larger randomized controlled trials, assessing safety and efficacy of sequential BCG and HA
administration.
Trial registration: NCT02207608 (ClinicalTrials.gov) 01/08/2014
Policlinico Tor Vergata Ethics Committee, resolution n 69–2011.
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Bacillus Calmette–Guérin (BCG) is considered the most
effective treatment to increase disease-free interval and
reduce progression of non-muscle invasive bladder cancer
(NMIBC) [1]. Although considered safe, BCG can produce
both local and systemic side effects leading to treatment
discontinuation or interruption. The most common local* Correspondence: efinazzi@tin.it
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unless otherwise stated.side-effects of BCG intravesical instillations include
cystitis, characterized by irritative voiding symptoms and
hematuria, which occur in approximately 75% of all pa-
tients. More rarely, serious local adverse events as a result
of BCG infection, such as symptomatic granulomatous
prostatitis and epididymo-orchitis, might occur and
require permanent discontinuation of BCG treatment.
Systemic side-effects include flu-like symptoms, such as
general malaise and fever, occuring in approximately 40%
of patients. A high persistent fever might be related to
BCG infection or sepsis. Local and systemic side-effects
might lead to discontinue intravesical BCG treatment in
approximately 20% of patients [2]. Up to 54% of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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peutic agents to treat superficial bladder tumours can be
affected by nonbacterial cystitis [3].
Several solutions have been proposed to reduce the
occurrence of side effects from BCG with the aim to limit
BCG discontinuation and the concomitant discomfort
during endovesical treatment. Some Authors have pro-
posed to avoid BCG administration in case of TUR within
previous 2 weeks, traumatic catheterization, macroscopic
hematuria, urethral stenosis, active tuberculosis, prior
Bacillus Calmette–Guérin sepsis, immuno-suppression
or urinary tract infection [4]. Other procedures include
the prophylactic administration of isoniazid [5] or oflox-
acin [6,7] or usually involve BCG dose reductions [8]. In
common practice antimicrobials, anticholinergics, an-
aesthetics and analgesics are often used to relieve
patients’ symptoms.
Glycosaminoglycan (GAG) substitution therapy is an
emerging treatment of Bladder Pain Syndrome/Intersti-
tial Cystitis (BPS/IC) and response rates between 30%
and 80% have been described with intravesical administra-
tion of various GAGs (hyaluronic acid, pentosan polysul-
fate, heparin, chondroitin sulfate, and dimethyl sulfoxide)
[9,10]. Few papers report the results of GAG substitution
therapy in the treatment of radiation and chemical cystitis
[9,10]. To our knowledge, to date, only two papers have
described GAG use in the treatment of BCG local side
effects; this papers show very good results, with significant
reduction of lower urinary tract symptoms after intravesi-
cal administration of HA [11,12].
Aim of the present randomized pilot study was to
evaluate if the sequential administration of HA and BCG
could be safe in prevention of early recurrence and
progression of bladder tumor, and safe in reduction of
local side-effects in patients with high risk NMIBC.
Methods
This is a prospective randomized pilot study approved by
our institutional review board (Policlinico Tor Vergata
Ethics Committee, resolution n° 69–2011). Patients with
a diagnosis of a intermediate/high risk NMIBC, accord-
ing to the European Organization for Research and
Treatment of Cancer (EORTC) score [13] after trans-
urethral resection of bladder tumor (TURBT) were
eligible for this study.
Inclusion criteria were:
1. Hystologically proven non-muscle invasive bladder
cancer;
2. Indication to intravesical instillation of BCG
according to EAU guidelines;
3. Age > 18 years;
4. Willingness, to participate to the study;
5. Written informed consent.Exclusion criteria were:
1. Previous or ongoing BCG or different intravesical
instillations;
2. Urinary tract infections (UTI) or other known
pathologies of the lower urinary tract;
3. Indication for a radical cystectomy;
4. Severe systemic disorders, including neurological
pathologies, kidney, liver or heart failure;
5. Contraindications to BCG use.
Patients enrolled in the study started the intravesical
therapies within 4 weeks from the TURBT and were ran-
domized in two groups. We a priori decided to stop this
pilot study after reaching the number of 15 patients in
each group. Group A was sent to receive BCG (Immu-
cist®81 mg, Sanofi-Aventis Group) alone and Group B to
receive BCG (see previous reference) and HA 40 mg
(Cystistat, Mylan, Pittsburgh, PA, U.S.A.). BCG strain used
in our study was Connaught 3,4 ± 3 × 10(8) CFU, 81 mg
(Immucist®) in 50 cc of saline. BCG was administered by
means of a 2 ways 14 Ch Foley catheter latex and left in-
side the bladder for 60 minutes. After 60 minutes BCG
was evacuated, the bladder washed with saline and the
catheter removed. HA was administered intravesically
after every BCG evacuation in Group B. After HA admin-
istration and catheter removal, patients were instructed to
maintain HA in the bladder as long as possible, for at least
2 hours after administration. In Group A normal saline
was administered, so that all patients were blinded to the
administration of HA. Both groups received an induction
course of 6 weekly instillations of BCG.
A 1 to 10 Visual Analog Scale (VAS) for bladder pain
was considered the primary outcome measure of the
study and was evaluated in both groups before and after
the treatment. International Prostate Symptom Score
(IPSS) and number of micturitions per day were also
evaluated in both groups before starting and at the end
of the induction cycle of BCG instillations.
Patients were evaluated at three and six months by
means of cystoscopy and urine cytology for oncologic
follow-up. The number of patients with bladder tumor
recurrence was recorded in both groups at 6 month
follow-up.
Data are presented as mean ± standard deviation (SD).
The statistical analysis was conducted with a t Student
Test using a software Stata 12.0, and considering as
significant a p value ≤0.05.
Our manuscript adheres to CONSORT guidelines.
CONSORT checklist is shown in Additional file 1.
Results and discussion
30 subjects were enrolled in the study between January
and December 2011. Mean age was 67 (range 54–81): 23
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BCa with intermediate/high risk of progression according
to the European Organization for Research and Treatment
of Cancer (EORTC) score. Fifteen patients (12 male and 3
female) were randomly assigned to Group A and 15 pa-
tients (11 male and 4 female) to Group B. Clinical and
pathologic features of patients are shown in Table 1.
Only one out of 30 (3,3%) patients in Group A dropped
out from the protocol, for local side effects (urgency, fre-
quency and burning micturition), while all Patients in
Group B completed the induction cycle with intravesical
BCG. The results are shown in Table 2.
Mean pre-treatment VAS was comparable in the two
groups (4.46 (2;10) for Group A and 4.86 (2;8) for Group
B, p = 0.56). After treatments mean VAS was signifi-
cantly lower in group B (4.2 (2;7) vs. 5.53 (4;7) in Group
A, p = 0.04). VAS post treatment was increased in Group
A and reduced in Group B: difference in post vs pre-
treatment VAS was significantly lower in Group B























≤ 9 intermediate 10 (33%)
10-17 high 20 (67%)
EORTC progressive score
≤6 intermediate 11 (36%)
7-23 high 19 (64%)Mean pre-treatment IPSS was comparable in both
groups (13.93 (8;24) in Group A and 14.73 (9;22) in
Group B, p = 0.6). After treatment, mean IPSS was
slightly lower in group B (15.26 (11;21) vs. 17.46 (13;21)
in Group A, even if the difference was not statistically
significant p = 0.1). IPSS increase post treatment was
significantly lower in Group B than in Group A (0.53
(−3;2) vs. 3.53 (−3;10) in Group A, p = 0.02).
Mean pre-treatment number of daily micturitions was
comparable in the two groups (10.26 (7;15) for Group A
and 10.8 (7;16) for Group B, p = 0.53). After treatment,
we failed to find a significant difference in number of
daily micturitions between the two groups (11.26 (9;13)
in Group A and 10.73 (7;14) in Group B, p = 0.44). On
the other hand, there was no increase in number of daily
micturitions in Group B and a slight increase in Group
A: this difference was significant (−0.066 (−2;1) for
Group B and 1 (−2;5) for Group A, p = 0.04).
At 6 month follow-up 3/15 (21%) pts of Group A (in-
cluding the patient who dropped out from the inductionGroup A (BCG) Group B (BCG + HA)
12 (80%) 11 (73%)
3 (20%) 4 (27%)
66 68
54-75 60-81
5 (33%) 4 (27%)
10 (67%) 11 (53%)
1,5 cm 1,5 cm
5 cm – 40 cm 5 cm – 50 cm
9 (60%) 8 (53%)
6 (40%) 7 (47%)
3 (20%) 5 (33%)
4 (27%) 4 (27%)
6 (40%) 4 (27%)
5 (33%) 7 (46%)
6 (40%) 4 (27%)
9 (60%) 11 (73%)
6 (40%) 5 (33%)
9 (60%) 10 (67%)
Table 2 Results of VAS, IPSS and bladder diaries at baseline and at the end of BCG induction cycle
Group A Group B p Group A Group B p Group A Group B p
Mean (SD) Pre Pre Post Post Difference
VAS (1–10) 4.5 (±2) 4.9 (±1.8) .56 5.8 (±1) 4.2 (±1.6) .04 1.5 (±0.7) −0.7 (±1.6) .0001
IPSS 13.9 (±4.4) 14.7 (±4.0) .60 17.5 (±2.6) 15.3 (±4) .10 3 (±3.5) 0.53 (±1.6) .02
n° daily micturitions 10.3 (±2.2) 10.8 (±2.4) .53 11.5 (±1.3) 10 .9 (±2.1) .44 1.23 (±1.7) 0.13 (±1) .04
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Group B had a recurrence of BCa. None of them had
BCa progression to muscle-invasive disease.
Several trials in the last two decades have investigated
BCG efficacy in reducing the risk of recurrence and pro-
gression in intermediate/high risk BCa showing that
BCG after TUR is superior to TUR alone or TUR and
conventional chemotherapy [14,15]. Two meta-analyses
have demonstrated that BCG therapy prevents, or at
least delays, the risk of tumour progression [16,17].
Despite of its great efficacy, BCG therapy has potential
local and systemic side effects that may either lead to
treatment cessation in up to 30% of patients or lead to
a delay or reduction in the number of instillations in
55–83% of patients [18].
The risk of increased toxicity during maintenance has
been questioned. According to the results of a European
Organization for Research and Treatment of Cancer
(EORTC) phase 3 trial [18], local side effects of BCG do
not increase during maintenance and systemic side
effects are more frequent during the first 6 mo of treat-
ment. However, a significant proportion of patients (84%
[19], 67.3% [18]), 86% [20] in the three most representa-
tive series) failed to complete the 3-yr maintenance
course for various reasons.
Several options have been proposed to decrease the oc-
currence of BCG side effects including the prophylactic
administration of isoniazid or ofloxacin, modifications to
the BCG treatment schedule and dose reductions. The
concomitant administration of isoniazid, has not been
found to decrease the incidence of BCG related side-
effects [5]. In contrast, ofloxacin reduced the incidence
of moderate to severe BCG related adverse events when
given prophylactically in a randomized double blind
trial in 115 patients [6,7]. However, further studies
are required to confirm these initial findings and to en-
sure that there is no impairment of treatment efficacy.
Martinez-Pineiro et al. investigated the BCG side effects
rate using a reduced dose of BCG. They found signifi-
cantly less toxicity on the reduced dose but recom-
mended the use of a full dose in the treatment of
high-risk patients [8]. In a second study in high-risk pa-
tients with T1G3 tumors and/or carcinoma in situ (CIS)
they concluded that one-third dose was indeed as effect-
ive as full dose, but was associated with significantly less
toxicity [21]. The final results of an EORTC-GU CancersGroup Randomized Study of Maintenance Bacillus
Calmette-Guerin in Intermediate- and High-risk Ta, T1
Papillary Carcinoma of the Urinary Bladder showed no
significant differences in toxicity between 1/3 dose and full
dose (FD) BCG. 1/3 dose with 1 yr of maintenance was
considered suboptimal compared with the standard FD
during 3 yr [22].
Despite of this great number of papers on BCG tox-
icity in literature, only two papers investigated the pos-
sible use of HA for treatment of BCG induced cystitis
[11,12] showing interesting results.
GAGs have been used extensively in BPS/IC with re-
sponse rates between 30% and 80% described with intra-
vesical administration of various substances such as HA,
PPS, heparin; chondroitin sulfate, and DMSO [23,24].
The efficacy of HA is based on several mechanisms that
aim on the urothelial function disorder present in BPS/
IC: on one side, HA reinforces the urine-tissue barrier
by integration in the GAG layer on the luminal surface
and the base of urothelial cells; on the other side, unique
anti-inflammatory mechanisms have been identified, like
inhibition of leukocyte migration, adherence of immune
complexes, and binding to specific receptors (I-CAM 1,
CD 44) involved in the inflammatory process [25-27].
Moreover studies on rat models have shown that HA
can inhibit bladder mast cell activation as well as the
inflammatory mediator release of urinary histamine, rat
mast cell protease-I and IL-6 [28] thus reducing their
pro-inflammatory activity.
Because of GAGs documented anti-inflammatory and
protective activity on the urothelium we considered the
possible use of these devices on the treatment of BCG
induced cystitis, even if one can argue that reducing
BCG side-effects can even impair BCG efficacy.
A correlation between BCG side-effects and treatment
efficacy has been reported by various authors, suggesting
that local side-effects have a significantly longer time to
first recurrence. However, patients with a better out-
come remain on treatment for a longer period of time
and receive more BCG, thus increasing their risk of
developing side-effects. Neither local nor systemic BCG
toxicity before 6 months was found to be a prognostic
factor for subsequent recurrence. Thus, it is not possible
to confirm that BCG toxicity is actually responsible for
an improved outcome and a causal effect cannot be
inferred from the data [29].
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reducing BCG side-effects during the induction cycle when
their frequency is higher than in the maintenance period
[18]. As described in the Results and discussion section,
VAS for bladder pain was significantly lower, at the end of
the induction cycle, in Group B (patients treated with HA).
It is important to underline that baseline VAS was relatively
high because obtained in patients who recently underwent
a TURBT. Interestingly, patients in Group B showed a
reduction, whilst those in Group A presented an increase
of VAS for pain. Indeed we failed to show between groups
a statistically significant difference in IPSS and number of
daily micturitions; nevertheless, the use of HA seems to
have reduced the appearance of lower urinary tract symp-
toms in Group B, with an increase of IPSS of only 0.53
points vs. a significantly higher increase in group A (3.53).
The same could be said about number of daily micturitions
that remained almost unchanged in Group B whilst was
increased after treatment in Group A. These results could
indicate a protective function of HA on the urothelium of
the bladder against the irritative activity of BCG.
One can argue that even ofloxacin when given prophy-
lactically before each BCG administration [6,7] can
achieve good results with a lower cost for the Health Care
System. Actually the use of Ofloxacin has significantly de-
creased the incidence of class 2 or higher AEs, but has not
improved class 1 AEs [6] while HA in our paper has dem-
onstrated to significantly reduce class 1 AEs. Moreover it
should be discussed if the prophylactic use of Ofloxacin
for 9 weeks could increase bacterial resistance.
These very preliminary data seem to support a pos-
sible role of HA in reducing BCG local side effects.
Nevertheless, our study has some limitations:
1. We have only a short follow up time;
2. It is a pilot study, with no power calculation;
3. Does not provide data on maintenance treatment;
4. Does not provide data on possible long term
interactions of HA with BCG efficacy;
5. It remains to be seen whether the administration of
HA after BCG is worth the benefit and increased costs.
The only outcome measures evaluated (VAS, IPSS,
daily micturitions) may have not detected important
efficacy end points, such as quality of life and relief of
painful micturition.
For all these reasons, no definitive conclusions should
be drawn. Nevertheless the data coming from this study
should be used to design a randomized controlled study
aimed to verify this hypothesis.
Conclusions
This pilot study provides, for the first time to our know-
ledge, evidence of a possible reduction of BCG localadverse events by using a sequential administration of
HA. Larger randomized controlled study, designed on
the basis of this pilot study are needed to assess how
clinically significant the association of HA to BCG could
be. In other words, further studies will have to investi-
gate if this association is worthy, having proven (statisti-
cally and clinically) significant reduction of local adverse
events of BCG, possibly causing a reduction of the num-
ber of patients who have to suspend or discontinue the
treatment with BCG, with a consequent reduction of its
efficacy. Furthermore, a possible interaction of HA with
BCG efficacy must be excluded before this association
could become part of a standard care. In conclusion, this
pilot study is only the first step, but further research is
needed to investigate the exact potentialities and role of
HA administered in patients treated by means of BCG
for NMIBC.
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